Literature DB >> 26004392

Low blood and vitreal BDNF, LXA4 and altered Th1/Th2 cytokine balance are potential risk factors for diabetic retinopathy.

Kuppan Kaviarasan1, Mohanlal Jithu1, Mohammad Arif Mulla2, Tarun Sharma2, Shanmuganathan Sivasankar1, Undurti Narasimha Das3, Narayanasamy Angayarkanni4.   

Abstract

OBJECTIVE: The study was conducted to observe the serum and vitreous levels of LXA4, BDNF and Th1/Th2 cytokines in type 2 diabetes mellitus (DM) and changes associated with diabetic retinopathy (DR). Further, the in vitro study was performed to analyze the exposure of BDNF and LXA4 on LPS-induced pro-inflammatory state in ARPE 19 cells.
MATERIALS AND METHODS: Totally 114 individuals were recruited in a prospective case control study. Of these, 27 were type 2 DM cases with no complications, 30 cases were type 2 DM with non proliferative diabetic retinopathy (NPDR), 30 were type 2 DM with proliferative diabetic retinopathy (PDR), and 27 were healthy control. ELISA was done to estimate the serum and vitreous levels of BDNF, VEGF and PEDF. FACS cytometric Bead Array system was used to analyze the serum cytokines.
RESULTS: The serum BDNF and LXA4 levels were significantly reduced in both NPDR and PDR cases compared to control (p=0.005, 0.01; p=0.033, 0.015). Serum IL-6 was significantly increased in the PDR group (p=0.04). BDNF showed a significant negative correlation with VEGF levels (r=-0.522, p<0.01) and positive correlation with IL-10 (r=0.67, p<0.05) in serum. A significant odds ratio for the serum BDNF (OR: 3.20, p=0.025) as well as serum IL-6 (OR: 1.244, p=0.042) indicated them as potential risk factors for progression of type 2 DM to DR. A significant decrease in both the LXA4 (p=0.013) and BDNF (p=0.0008) with increase in cytokines IL-6 and IL-10 levels were observed in the vitreous of PDR cases ((p=0.04, 0.01). In vitro studies showed that both LXA4 (10 nmol/L) and BDNF (500 pg) decreased the IL-6 levels (p=0.036, 0.0002), in LPS induced pro-inflammatory condition in ARPE 19 cells, thereby their anti-inflammatory effect.
CONCLUSIONS: This study reports that low serum BDNF and higher IL-6 levels are potential risk factors for DR in type 2 DM. This study supports the role of BDNF in modulating the pro- and anti-inflammatory cytokines, and low level of BDNF is associated with development of diabetic retinopathy.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BDNF; Cytokines; Diabetic retinopathy; LXA(4); Type 2 diabetes

Mesh:

Substances:

Year:  2015        PMID: 26004392     DOI: 10.1016/j.metabol.2015.04.005

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  33 in total

1.  Imbalance of the Nerve Growth Factor and Its Precursor: Implication in Diabetic Retinopathy.

Authors:  Riyaz Mohamed; Azza B El-Remessy
Journal:  J Clin Exp Ophthalmol       Date:  2015-10-25

Review 2.  The role of pro-resolving lipid mediators in ocular diseases.

Authors:  Jessica Wei; Karsten Gronert
Journal:  Mol Aspects Med       Date:  2017-04-06

3.  Differential Expression of BDNF and BIM in Streptozotocin-induced Diabetic Rat Retina After Fluoxetine Injection.

Authors:  Seong Taeck Kim; Yoon Young Chung; Hyo-In Hwang; Hye-Kyoung Shin; Ranju Choi; Yong Hyun Jun
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

Review 4.  Changes in aqueous and vitreous inflammatory cytokine levels in proliferative diabetic retinopathy: a systematic review and meta-analysis.

Authors:  Ryan H Mason; Samuel A Minaker; Gabriela Lahaie Luna; Priya Bapat; Armin Farahvash; Anubhav Garg; Nishaant Bhambra; Rajeev H Muni
Journal:  Eye (Lond)       Date:  2022-06-07       Impact factor: 4.456

5.  Assessment of macular findings by OCT angiography in patients without clinical signs of diabetic retinopathy: radiomics features for early screening of diabetic retinopathy.

Authors:  Mehrdad Afarid; Negar Mohsenipoor; Hossein Parsaei; Yalda Amirmoezzi; Mohsen Ghofrani-Jahromi; Peyman Jafari; Aliakbar Mohsenipour; Fatemeh Sanie-Jahromi
Journal:  BMC Ophthalmol       Date:  2022-06-27       Impact factor: 2.086

6.  Increased vitreal levels of interleukin-10 in diabetic retinopathy: a Meta-analysis.

Authors:  Wei Tan; Jing-Ling Zou; Shigeo Yoshida; Bing Jiang; Ye-Di Zhou
Journal:  Int J Ophthalmol       Date:  2020-09-18       Impact factor: 1.779

7.  Astrocyte-derived lipoxins A4 and B4 promote neuroprotection from acute and chronic injury.

Authors:  Izhar Livne-Bar; Jessica Wei; Hsin-Hua Liu; Samih Alqawlaq; Gah-Jone Won; Alessandra Tuccitto; Karsten Gronert; John G Flanagan; Jeremy M Sivak
Journal:  J Clin Invest       Date:  2017-11-06       Impact factor: 14.808

8.  VEGF Mediates Retinal Müller Cell Viability and Neuroprotection through BDNF in Diabetes.

Authors:  Yun-Zheng Le; Bei Xu; Ana J Chucair-Elliott; Huiru Zhang; Meili Zhu
Journal:  Biomolecules       Date:  2021-05-10

Review 9.  Molecular Markers of Diabetic Retinopathy: Potential Screening Tool of the Future?

Authors:  Priyia Pusparajah; Learn-Han Lee; Khalid Abdul Kadir
Journal:  Front Physiol       Date:  2016-06-01       Impact factor: 4.566

10.  Inverse Relationship between Serum Lipoxin A4 Level and the Risk of Metabolic Syndrome in a Middle-Aged Chinese Population.

Authors:  Dan Yu; Zhiye Xu; Xueyao Yin; Fenping Zheng; Xihua Lin; Qianqian Pan; Hong Li
Journal:  PLoS One       Date:  2015-11-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.